WELCOME TO MEDSHADOW. WE'VE UPDATED OUR LOOK!

New Psoriasis Med Demonstrates Efficacy, Safety Over Long Term

New Psoriasis Med Demonstrates Efficacy, Safety Over Long Term
Psoriasis on elbow. Medical treatment

A new medication approved by the FDA in March to treat psoriasis has demonstrated sustained efficacy, even after the drug is taken for more than a year.

Taltz (ixekizumab), a biologic medication, was also found to be more effective than another popular biologic already on the market called Enbrel (etarnecept). Both medications are given by injection.

Taltz works by targeting a pathway in the immune system, called IL-17, known to promote psoriasis.

The latest findings, published in the New England Journal of Medicine, are based on results from 3 clinical trials that enrolled almost 4,000 people. In the first trial, Taltz was compared against a placebo. However, in the other two, it was compared against a placebo and Enbrel for the first 12 weeks, and then just placebo after 12 weeks.

After the first 12 weeks, the Taltz injection was given either once a month or every 12 weeks. After 60 weeks, nearly 75% of the patients given the biologic once a month had only a minimal amount of psoriasis, compared to just 7% of patients taking the placebo.

In addition, during the 12-week intial period of the studies, Taltz was more effective than Enbrel by a wide margin.

“Based on these findings, we expect that 80% of patients will have an extremely high response rate to ixekizumab, and about 40% will be completely cleared of psoriasis,” lead author Kenneth Gordon, MD, a professor of dermatology at Northwestern University Feinberg School of Medicine, said in a statement.

Like most medications, side effects were seen with some patients taking Taltz. These adverse events included slightly higher rates of low white blood cell count (neutropenia), yeast infection and inflammatory bowel disease compared to placebo. The safety of the biologic past 60 weeks of use is also not known.

Also, the research was funded by Eli Lilly, Taltz’s manufactuer. In addition, Gordon is a paid consultant for the drugmaker.

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Was This Article Helpful?

Show Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x